Why the study?
Does the measurement of prothrombin fragment F1+2 detect hypercoagulable and hypocoagulable states in patients with DIC or on warfarin therapy compared to healthy subjects?
Does the measurement of prothrombin fragment F1+2 detect hypercoagulable and hypocoagulable states in patients with DIC or on warfarin therapy compared to healthy subjects?
Answers are grounded in this paper and cite their sources.
Plasma F1+2 measured by a novel ELISA is a sensitive biomarker for detecting both hypercoagulable (DIC) and hypocoagulable (warfarin therapy) states.
Plasma levels of prothrombin fragment F1+2 were measured by a newly developed enzyme-linked immunosorbent assay (ELISA) in 44 healthy subjects, 34 patients with disseminated intravascular coagulation and 22 patients under stabilized warfarin therapy (INR>1.8). In this assay, rabbit antibody against F1+2 was used as a catching antibody, and rabbit antiprothrombin antibody as a tagging antibody. The mean plasma level of F1+2 in healthy subjects was 0.60±0.15 (SD) nM with a 95% range of 0.30-0.90nM. Plasma F1+2 was markedly elevated in patients with disseminated intravascular coagulation (6.02±2.90nM). In warfarin-treated patients, F1+2 concentrations (0.21±0.01nM) were significantly lower than those in healthy subjects. These results indicate that the measurement of F1+2 in plasma would be a sensitive and useful parameter for detection of hypercoagulable as well as hypocoagulable states in various diseases.
No takes yet. Share an insight, caveat, or question.
Takahashi et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: